Skip to main
ACON
ACON logo

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc demonstrates impressive momentum in its financial performance, highlighted by a 31% year-over-year increase in Q3 revenue, totaling $18,942, driven by a significant 89% rise in Nociscan report volumes. The company is aggressively investing in sales and marketing, as evidenced by a staggering 172% year-over-year increase in expenses, reflecting a strategic focus on expanding market presence and clinical trial support. Additionally, Aclarion's commercial agreements with prominent healthcare institutions across various states underscore its strong market position and the accelerating uptake of its Nociscan platform.

Bears say

Aclarion Inc faces significant challenges that contribute to a negative outlook on its stock, notably slower-than-expected traction with both surgeons and payers, which can hinder revenue growth. The company has consistently adjusted its FY25 EPS estimates downward, with the latest forecast showing an EPS of $(15.13) due to rising marketing and administrative expenses, indicating ongoing operational inefficiencies. Furthermore, risks surrounding liquidity, regulatory approvals, and competition compound concerns regarding Aclarion's ability to commercialize its Nociscan product effectively in a competitive healthcare market.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.